BioSpace News Archive

LIXTE Biotechnology Holdings, Inc., notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of SGO, that a subset of patients with OCCC treated with immune checkpoint inhibitors lived significantly longer than most patients with the same disease treated with the same regimens.

CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the fourth quarter and full-year ended December 31, 2021 and provided a corporate update.

Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to welcome Andrew “Drew” M. Reynolds to the Psychemedics Board of Directors effective April 4th, 2022.

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, announced that it has entered into a new $36.0 million credit facility with a commercial bank.

Palisade Bio, Inc. (Nasdaq: PALI), announced that the Company received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery.

Applied Genetic Technologies Corporation announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common stock for gross proceeds of approximately $9.8 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by AGTC.

InnoSIGN, a precision medicine company, announced that it raised an $8M Series A financing.

Bimini Health Tech, a commercial-stage medical device company, and Arthrex, Inc., a global leader in minimally invasive orthopedic technology, have entered into an exclusive partnership to globally commercialize Bimini’s Autopose family of products for the harvesting and micro-fragmentation of adipose tissue.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that CEO Mark Erlander, Ph.D., has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 AM - 5:00 PM EDT.

KSQ Therapeutics (KSQ), a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, will give an oral presentation as part of the “New Drugs on the Horizon: Part 1” session at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting in New Orleans.